GlassScriptPhysician profile
Syeda Hamadani
NPI 1710246848
$5,855.20
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,924 · 2020: $3,299 · 2021: $523 · 2022: $109.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $3,610.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $528.74 | 2019-2022 | |
| Glaxosmithkline, LLC. | $311.55 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $213.56 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.69 | 2019-2021 | |
| Csl Behring | $127.52 | 2019-2022 | |
| Octapharma USA, INC. | $102.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $88.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $88.16 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.96 | 2020-2021 | |
| Mylan Specialty L.P. | $70.54 | 2019-2020 | |
| Grifols USA, LLC | $64.02 | 2019-2020 | |
| Pfizer INC. | $58.89 | 2019-2021 | |
| Horizon Therapeutics Plc | $58.26 | 2019-2020 | |
| Shire North American Group INC | $42.03 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $39.95 | 2019 | |
| Aimmune Therapeutics, INC. | $37.96 | 2021 | |
| Genentech USA, INC. | $33.32 | 2019-2020 | |
| Amgen INC. | $27.22 | 2021 | |
| Genzyme Corporation | $26.16 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $24.38 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.43 | 2019 | |
| Sunovion Pharmaceuticals INC. | $15.81 | 2019 | |
| Boston Scientific Corporation | $15.45 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.76 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syeda Hamadani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.